ESMO 2024 – changing FDA stance could haunt Astra’s Niagara win
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
The company takes another project from Taris into phase 3 as it chases a $5bn market.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.